FDA Approves Wearable TTFields Therapy for Locally Advanced Pancreatic Cancer
The FDA approved Optune Pax, a wearable device delivering abdominal tumor treating fields (TTFields) to treat locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, based on PANOVA-3 which showed longer median overall survival and pain-free survival with TTFields versus chemotherapy alone; skin reactions were common; the device costs about $21,000 per month and includes patches, a generator, and support services.